ProMIS Neurosciences Closes First Tranche of Private Placement

NEXT STORY
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
PREV STORY
Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases

author_avatar
NASDAQ Market News

Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia

NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global ...

author_avatar
NASDAQ Market News

ADMA Biologics Resubmits Biologics License Application for RI-002

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, ...

author_avatar
NASDAQ Market News